The stock price of Curiox Biosystems, recently listed on the KOSDAQ market, is rebounding after just one day. Despite the recent price increase, securities firms' analyses suggesting a strong potential for a 'multi-bagger' in the mid to long term appear to be influencing the stock price.
As of 9:08 AM on the 29th, Curiox Biosystems was trading at 38,350 KRW, up 2,500 KRW (6.97%) compared to the previous trading day.
SK Securities described Curiox Biosystems as a bio materials and components company poised to become a game changer in the 19 trillion KRW cell analysis market.
Researcher Dong-geon Lee of SK Securities explained, "Curiox has developed the world's only non-centrifugal based cell analysis process automation technology (LW)" and "has established a product lineup tailored to customer needs, including MINI1000, HT2000, and AUTO1000, which apply this technology."
He added, "The LW technology overcomes the limitations of the existing cell analysis process (centrifugation method), which is manually performed, takes a long time, and results can vary depending on skill level," and "LW technology automates all processes from sample injection to analysis result output."
Furthermore, he stated, "It reduces washing time by about 80% and ensures high data reproducibility and accuracy," and "it also offers the advantage of reducing costs for reagents and consumables by approximately 50% compared to existing methods."
He analyzed, "The cell analysis process is essential for both new drug development and diagnostics, with the global market size reaching approximately 19 trillion KRW as of 2023," and "the potential market is 1 trillion KRW if global standards are adopted, and Curiox has secured 18 out of the top 20 global pharmaceutical companies as clients."
He emphasized, "A key point to watch is the possibility of LW products being adopted as the standard in cell analysis standardization recommendations," and "Curiox is the only analysis process company participating in the ‘Cell Analysis Standardization Consortium’ involving the FDA and the U.S. National Institute of Standards and Technology (NIST)." He continued, "It is expected that LW products will be adopted as the analysis process standard in the cell analysis standardization recommendations scheduled for release next year," and "a senior researcher leading NIST’s cell analysis standardization consortium also highlighted the effectiveness of cell analysis process automation using the LW AUTO product at a global conference."
The researcher said, "Curiox is currently reviewing the transition from existing legacy processes to LW-based processes with commercialized CAR-T therapy developers," and "results could be confirmed as early as next month." He predicted, "If adopted as the production process for FDA-approved CAR-T therapies, it will act as another explosive sales growth trigger."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
